PROCEPT BioRobotics reports $94.5 million Q2 revenue
PROCEPT BioRobotics reported second-quarter revenue of $94.5 million, up 19% year on year, while U.S. procedures using its systems increased 21% to more than 13,100.
Evidence notes
- The company delivered 65 HYDROS systems during the quarter.
- U.S. procedure volume exceeded 13,100, representing 21% year-on-year growth.
- PROCEPT maintained full-year revenue guidance of $390 million to $410 million.
Company context
PROCEPT BioRobotics develops surgical robotic systems for Aquablation therapy, including image-guided robotic waterjet treatment for benign prostatic hyperplasia.